- The funding will scale Immuneel’s GMP manufacturing capacity to treat more patients in India and internationally
- Democratise global access to lifesaving cell and gene therapies
- Support the commercialisation of Qartemi- India’s first-approved global CAR-T therapy for NonHodgkin Lymphoma and Leukaemia
- Accelerate Immuneel’s international market entry across Asia Pacific and Middle East
- Expand Immuneel’s research and development pipeline for global novel cell and gene therapies
June 8, 2026, Bangalore, India – Immuneel Therapeutics, a pioneering integrated cell
and gene therapy platform, today announced the successful close of its ₹100 crore plus
Series B financing. The round saw participation from new investors including
Singularity AMC, Rainmatter by Zerodha, and several High-Net-Worth Individuals
alongside strong continued support from existing investors including Kiran
Mazumdar-Shaw, Eight Roads Ventures, and F-Prime Capital.
The financing will directly fund key strategic priorities: scaling Immuneel’s GMP
manufacturing capacity, advancing its next-generation deep-tech cell and gene therapy
pipeline toward clinical milestones, supporting the commercialisation of Qartemi, and
accelerating international market entry across Asia Pacific and Middle East.
Following the successful commercial launch of Qartemi, approved CAR-T therapy for
Non-Hodgkin Lymphoma, Immuneel Therapeutics is now extending its reach into high growth emerging markets and progressing clinical co-development partnerships in
Australia and Southeast Asia. The company operates India’s first international standard
CAR-T platform to deliver world-class therapies at a fraction of the Western costs.
Kiran Mazumdar-Shaw, Founder of Immuneel Therapeutics, commented: “This
company was founded with the belief that advanced cell therapies should not remain
confined to a small segment of patients or a handful of geographies. This fundraise
strengthens our ability to build a globally competitive CAR-T platform from India
combining deep science, scalable manufacturing and significantly improved
affordability. We believe India can play a meaningful role in shaping the future of cell and
gene therapy for the world.”
Amit Mookim, Chief Executive Officer of Immuneel Therapeutics, added: “Qartemi’s
commercialisation proved we can deliver world-class CAR-T outcomes at a fraction of
Western costs. This Series B financing accelerates what comes next: a bold international
expansion and a next-generation pipeline that will redefine how cell therapies reach
patients globally. We are not just building a company—we are building a new global
standard of care, from India.”
Aravind Viswanathan, Senior Operating Partner at Singularity AMC, stated: “CAR-T
cell therapy represents one of the most consequential breakthroughs in modern
oncology—the ability to engineer a patient’s own immune cells to precisely target and
eliminate cancer is a paradigm shift that was, until recently, accessible only to patients
in the wealthiest corners of the world. Immuneel is changing that. What excites us most
is the breadth of their pipeline: from expanding into new blood cancer indications to nextgeneration modalities that could dramatically reduce the cost and complexity of
treatment. Each of these advances has the potential to extend lifesaving therapy to tens
of thousands of patients in India and beyond, who currently have no access to it. We are
proud to partner with this world-class team as they disrupt the market and scale their
premium-outcome therapeutics globally.”
Nithin Kamath, Founder & CEO at Zerodha and Rainmatter, commented: “Cancer
remains one of the most devastating diseases of our time and the most advanced
treatments have been out of reach for most Indians. We’re living a moment where biotech
innovations are genuinely changing what’s possible and we’re excited to support
Immuneel who are bringing Cell and gene therapies, including CAR-T to Indian patients
with a focus on outcomes and accessibility. We believe in supporting innovations that
create deep, long-term societal impact. Immuneel’s mission to bridge the accessibility
gap for lifesaving cell and gene therapies aligns perfectly with our vision, and we are
excited to back their journey towards equitable healthcare and global expansion.”
